IDEXX Laboratories Inc

IDXX

Equity

ISIN null / Valor 940695

NASDAQ (2025-11-21)

USD 725.91+5.30%

IDEXX Laboratories Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

IDEXX Laboratories Inc is a global leader in providing diagnostic products and services for veterinary practices, livestock, poultry, dairy, and water testing. The company offers a wide range of biological materials testing, laboratory animal diagnostic services, analyzers, blood gas and electrolyte analyzers, pet-side tests, bench-top laboratory systems, diagnostic tests for antibiotic residue detection in milk, and water microbiology tests for ensuring the safety of drinking water. IDEXX also provides practice management software solutions for veterinarian practices, including IDEXX Pet Health Network Pro, VetConnect PLUS, and Cornerstone. With a focus on animal health and safety, IDEXX Laboratories Inc plays a crucial role in managing herd and flock health, as well as ensuring the safety of water supplies for over two billion people in 100 countries worldwide.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

In Q2 2025, IDEXX Laboratories Inc. achieved an 11% increase in revenue as reported and a 9% organic growth. This growth was primarily driven by an 11% reported and 10% organic increase in the Companion Animal Group (CAG) segment, along with a 9% reported and 8% organic growth in Water revenues.

EPS Performance

The company delivered earnings per share (EPS) of $3.63 for the second quarter, marking a 49% increase as reported and a 17% increase on a comparable basis. This growth was supported by operational efficiencies and benefits from discrete tax reserve releases.

Record Instrument Placements

IDEXX achieved record quarterly instrument placements, including nearly 2,400 IDEXX inVue Dx™ systems. This milestone underscores the company’s strong global commercial execution and the adoption of its innovative diagnostic technologies by veterinarians.

2025 Guidance Update

IDEXX raised its 2025 revenue guidance to a range of $4,205 million to $4,280 million, reflecting an approximate 2% increase at the midpoint. Additionally, the company updated its EPS outlook to $12.40 - $12.76, representing a $0.40 increase at the midpoint, supported by higher revenue projections and improved operating margins.

Companion Animal Group (CAG) Performance

The CAG segment saw a 9% reported and 7% organic growth in diagnostics recurring revenue, fueled by strong international performance and increased diagnostic utilization. IDEXX VetLab® consumables also contributed significantly with a 15% reported and 14% organic revenue increase.

Summarized from source with an LLMView Source

Key figures

73.4%1Y

75.8%3Y

56.3%5Y

Performance

40.9%1Y

34.5%3Y

34.7%5Y

Volatility